Lineage Cell Therapeutics (LCTX) Consolidated Net Income (2010 - 2026)

Lineage Cell Therapeutics' Consolidated Net Income history runs 17 years deep, the most recent figure standing at -$19.3 million for Q1 2026.

• In Q1 2026, Consolidated Net Income fell 183.83% year-over-year to -$19.3 million; the TTM figure through Mar 2026 stood at -$67.6 million (down 258.76% YoY), while the FY2025 annual figure was -$63.4 million, down 241.01% from the prior year.
• Consolidated Net Income for Q1 2026 stood at -$19.3 million, down from -$6.9 million in the prior quarter.
• The five-year high for Consolidated Net Income was -$3.0 million in Q3 2024, with the low at -$22.5 million in Q2 2025.
• The 5-year median for Consolidated Net Income is -$6.6 million (2024), against an average of -$8.3 million.
• The sharpest annual moves came in 2022 and 2025: Consolidated Net Income jumped 77.43% in 2022, then plunged 528.02% in 2025.
• Lineage Cell Therapeutics' Consolidated Net Income stood at -$6.3 million in 2022, then increased by 25.42% to -$4.7 million in 2023, then jumped by 31.06% to -$3.2 million in 2024, then slumped by 110.98% to -$6.9 million in 2025, then sank by 181.89% to -$19.3 million in 2026.
• Business Quant data shows LCTX's Consolidated Net Income at -$19.3 million in Q1 2026, -$6.9 million in Q4 2025, and -$18.8 million in Q3 2025.